Balcom Alexandra — SEC Form 4 filings
SEC reporting owner CIK 1862147. 27 Form 4 filings on record with FilingPulse; latest filed 2026-07-15.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2024-01-09 to 2026-07-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 78 legs across 21 filings — 299,367 shares, $27,469,420 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 79.
- Largest priced transaction: sale of 20,000 shares @ $85.06 ($1,701,200) in Nuvalent, Inc., filed 2025-10-01.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Nuvalent, Inc. (NUVL) | Chief Financial Officer | 25 | — | 78 legs · 299,367 sh · $27,469,420 | 77 |
| CRESCENT BIOPHARMA, INC. (CBIO) | Director | 2 | — | — | 2 |
Form 4 filings — Balcom Alexandra
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-15 | 4 | Nuvalent, Inc. (NUVL) | Code (U): 44,433 @ $124 · Disposition to issuer (D): 41,100 · Grant/award (A): 14,350 @ $0 · Disposition to issuer (D): 14,350 · Disposition to issuer (D): 131,637 (derivative) · Disposition to issuer (D): 8,016 (derivative) · +5 more | EDGAR |
| 2026-07-06 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 5,384 @ $6.89 · Option exercise (M): 6,046 @ $18.93 · Sale (S): 11,430 @ $123.58 · Option exercise (M): 5,384 (derivative) @ $0 · Option exercise (M): 6,046 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Grant/award (A): 11,050 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 11,430 @ $6.89 · Sale (S): 960 @ $94.87 · Sale (S): 2,170 @ $95.99 · Sale (S): 900 @ $97.68 · Sale (S): 1,200 @ $98.57 · Sale (S): 3,133 @ $99.86 · +4 more | EDGAR |
| 2026-05-05 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 7,159 @ $1.08 · Option exercise (M): 4,271 @ $6.89 · Sale (S): 3,872 @ $98.42 · Sale (S): 7,434 @ $99.29 · Sale (S): 124 @ $99.97 · Option exercise (M): 7,159 (derivative) @ $0 · +1 more | EDGAR |
| 2026-04-03 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 11,430 @ $1.08 · Sale (S): 3,544 @ $104.39 · Sale (S): 5,417 @ $105.30 · Sale (S): 2,469 @ $106.18 · Option exercise (M): 11,430 (derivative) @ $0 | EDGAR |
| 2026-03-26 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 11,430 @ $1.08 · Sale (S): 2,599 @ $95.03 · Sale (S): 7,671 @ $95.88 · Sale (S): 1,160 @ $96.50 · Sale (S): 13,700 @ $100.16 · Option exercise (M): 11,430 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Nuvalent, Inc. (NUVL) | Sale (S): 871 @ $96.06 · Sale (S): 1,119 @ $96.85 · Sale (S): 1,929 @ $97.96 · Sale (S): 317 @ $98.52 · Sale (S): 1,321 @ $96.75 · Sale (S): 1,635 @ $97.33 · +3 more | EDGAR |
| 2025-12-23 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 34,500 @ $1.08 · Option exercise (M): 34,500 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Nuvalent, Inc. (NUVL) | Sale (S): 6,984 @ $110.31 · Sale (S): 100 @ $111.32 | EDGAR |
| 2025-11-19 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 6,875 @ $6.89 · Option exercise (M): 13,125 @ $72.35 · Sale (S): 3,609 @ $93.80 · Sale (S): 3,266 @ $95.12 · Sale (S): 4,496 @ $100.58 · Sale (S): 3,194 @ $102.13 · +8 more | EDGAR |
| 2025-10-17 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 1,683 @ $18.93 · Sale (S): 1,683 @ $85.57 · Option exercise (M): 1,683 (derivative) @ $0 | EDGAR |
| 2025-10-15 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 6,875 @ $6.89 · Option exercise (M): 13,125 @ $18.93 · Sale (S): 6,138 @ $87.90 · Sale (S): 12,266 @ $88.73 · Sale (S): 1,596 @ $89.22 · Option exercise (M): 20,000 @ $18.93 · +7 more | EDGAR |
| 2025-10-03 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 16,787 @ $6.89 · Option exercise (M): 3,213 @ $18.93 · Sale (S): 19,030 @ $85.43 · Sale (S): 970 @ $86.37 · Option exercise (M): 16,787 (derivative) @ $0 · Option exercise (M): 3,213 (derivative) @ $0 | EDGAR |
| 2025-10-01 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 7,588 @ $6.89 · Sale (S): 7,588 @ $85.01 · Option exercise (M): 20,000 @ $6.89 · Sale (S): 20,000 @ $85.06 · Option exercise (M): 7,588 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-07-17 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 5,300 @ $18.93 · Sale (S): 2,484 @ $82.67 · Sale (S): 1,888 @ $83.87 · Sale (S): 874 @ $84.91 · Sale (S): 54 @ $85.48 · Option exercise (M): 14,700 @ $18.93 · +3 more | EDGAR |
| 2025-07-01 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 20,000 @ $18.93 · Sale (S): 20,000 @ $80.02 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | GLYCOMIMETICS INC (CBIO) | Grant/award (A): 9,023 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 18,750 @ $0 · Sale (S): 1,152 @ $78.28 · Sale (S): 691 @ $79.33 · Sale (S): 2,173 @ $80.54 · Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 4,728 @ $1.08 · Option exercise (M): 8,972 @ $6.89 · Option exercise (M): 4,728 (derivative) @ $0 · Option exercise (M): 8,972 (derivative) @ $0 | EDGAR |
| 2024-12-03 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 10,000 @ $27.85 · Sale (S): 8,142 @ $95.69 · Sale (S): 1,858 @ $96.25 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-11-04 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 10,000 @ $27.85 · Sale (S): 1,980 @ $88.25 · Sale (S): 6,320 @ $89.17 · Sale (S): 1,600 @ $90.31 · Sale (S): 100 @ $90.94 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 10,000 @ $27.85 · Sale (S): 700 @ $98.88 · Sale (S): 1,305 @ $100.09 · Sale (S): 5,032 @ $101.13 · Sale (S): 2,963 @ $101.89 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-09-04 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 10,000 @ $27.85 · Sale (S): 5,231 @ $83.87 · Sale (S): 4,481 @ $84.55 · Sale (S): 288 @ $85.96 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-08-02 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 10,000 @ $27.85 · Sale (S): 896 @ $77.02 · Sale (S): 597 @ $78.05 · Sale (S): 5,723 @ $79.44 · Sale (S): 1,649 @ $80.38 · Sale (S): 1,135 @ $81.31 · +1 more | EDGAR |
| 2024-07-02 | 4 | Nuvalent, Inc. (NUVL) | Option exercise (M): 10,000 @ $27.85 · Sale (S): 7,565 @ $75.15 · Sale (S): 1,863 @ $76.19 · Sale (S): 572 @ $76.73 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-01-09 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 33,300 @ $0 · Grant/award (A): 47,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-09 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1862147 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →